See Bull Run's current company pages for Zydus Lifesciences and Lupin. Investors can also compare Lupin with Bull Run's Cipla vs Lupin and Dr Reddy's vs Lupin analyses.

Q1 FY27 scorecard: almost equal revenue, very different profit conversion

Zydus grew revenue strongly—but profit declined

Revenue from operations increased approximately 22% to ₹8,017 crore.

EBITDA declined around 8% to ₹1,929 crore.

EBITDA margin fell from approximately 31.8% to 24.1%.

PAT declined about 36% to ₹940 crore.

This divergence is the defining Q1 issue.

Why did Zydus margins fall despite 22% revenue growth?

Several effects hit profitability:

• higher operating costs;
• acquisition and integration expenses;
• investment behind the specialty and branded platform;
• higher employee costs;
• higher financing costs;
• generic pricing pressure;
• freight and other operating pressure.

The important point is that part of the margin compression is linked to investment for future growth.

But investment is valuable only if the future specialty revenue materializes.

Lupin produced the cleaner income statement

Lupin sales increased 33.3% to approximately ₹8,217 crore.

EBITDA increased 42.8% to approximately ₹2,580 crore.

EBITDA margin reached 31.4%.

PAT increased 16% to ₹1,417 crore.

Gross margin reached 74.6%.

This shows both revenue growth and operating leverage.

The US explains much of Lupin's lead

Lupin therefore generated only around 11–12% more US revenue.

The percentage growth gap was much larger.

Lupin is currently benefiting from differentiated products and complex-generics execution.

Lupin's US portfolio is increasingly difficult to replicate

The company has spent years building:

• complex generics;
• respiratory products;
• injectables;
• long-acting injectables;
• biosimilars;
• limited-competition oral products;
• selected specialty medicines.

Complex products can attract fewer competitors and sustain better economics than conventional oral-solid generics.

Lupin's scale in US prescriptions is significant

Lupin marketed 149 generic products in the United States at the end of Q1.

It remained the third-largest pharmaceutical player in the US generic market by prescriptions under company-cited IQVIA data.

Lupin was market leader in 56 marketed generics and among the top three in 112.

This creates commercial scale that makes each new approval easier to launch.

The pipeline remains deep

Lupin had:

• 429 cumulative ANDA filings;
• 350 approvals;
• 50 first-to-file filings;
• 21 exclusive first-to-file opportunities.

It received six ANDA approvals and launched three products during Q1.

The pipeline is essential because today's limited-competition products eventually face new competitors.

Zydus is trying to reduce dependence on conventional US generics

Zydus's North America business remains very large.

It represented approximately 40% of consolidated revenue.

But the company is increasingly emphasizing:

• branded specialty products;
• orphan and rare-disease products;
• 505(b)(2) medicines;
• internally developed innovation;
• biosimilars.

This is strategically important because commodity generics tend to face persistent price erosion.

Branded products are becoming meaningful in Zydus's US business

The current portfolio includes acquired and internally developed opportunities.

The objective is to create a US business where earnings are less dependent on individual generic launches.

Saroglitazar could materially change Zydus's profile

Saroglitazar is an internally developed molecule from Zydus.

The US FDA granted Priority Review to the company's application for Primary Biliary Cholangitis.

The FDA assigned a target action date of November 27, 2026.

If approved, Zydus has said it plans to prepare for a US launch thereafter.

Why is Saroglitazar strategically important?

It represents something much more valuable than another generic approval.

Zydus owns the underlying innovation.

A successful branded drug can create:

• product differentiation;
• greater pricing power;
• physician-brand equity;
• longer commercial durability;
• international licensing opportunities.

The trade-off is clinical and commercial risk.

The Phase 3 data were strong enough to secure Priority Review

In the pivotal EPICS-III programme, Zydus reported a significant biochemical-response benefit versus placebo.

That does not guarantee FDA approval.

But it establishes a meaningful clinical basis for the regulatory application.

November 27 therefore becomes a genuine company-specific catalyst.

Lupin does not have an equivalent near-term internally developed US catalyst

Lupin's strategy is more diversified across:

• complex generics;
• respiratory;
• biosimilars;
• selected specialty products;
• in-licensed therapies.

This produces lower binary dependence on one internally developed medicine.

But it also means less upside from owning a successful proprietary global drug.

The most unusual fact: Zydus and Lupin are also partners

In 2023, Lupin signed an agreement to co-market Zydus's Saroglitazar in India under the brand LINVAS.

Zydus continued marketing the molecule under its own brands.

This arrangement allows:

• Zydus to monetize its intellectual property through another sales network;
• Lupin to add an innovative liver-disease therapy without discovering the molecule itself.

The partnership expanded again with semaglutide

In March 2026, Lupin entered another licensing and supply agreement with Zydus for an innovative semaglutide injection in India.

Lupin received semi-exclusive co-marketing rights.

Zydus continues selling the product under its own brands.

This is a powerful example of how pharmaceutical competitors can collaborate where their capabilities are complementary.

Zydus owns development capability; Lupin contributes distribution

Zydus brings:

• drug development;
• manufacturing;
• innovation;
• regulatory expertise.

Lupin brings:

• a large Indian field force;
• strong chronic-therapy relationships;
• gastroenterology and metabolic reach;
• brand commercialization.

Both companies can earn from the same molecule.

India growth currently favours Zydus

Zydus India formulations generated approximately ₹1,816 crore.

The business grew 20% year on year.

Lupin India sales generated approximately ₹2,380 crore and grew 13.9%.

Lupin therefore has the larger India business.

Zydus is currently growing faster.

Zydus outperformed across multiple Indian therapies

Company materials highlighted growth across:

• cardiology;
• diabetology;
• gynaecology;
• anti-infectives;
• pain management;
• oncology;
• nephrology.

Zydus retained leadership in oncology and improved rankings across several chronic categories.

This broad growth lowers dependence on one domestic therapy.

Lupin remains stronger in several major chronic therapies

Lupin's India franchise has strong positions in:

• respiratory;
• cardiac;
• diabetes;
• gastroenterology;
• CNS;
• urology;
• women's health.

Its chronic share had reached roughly two-thirds of India formulations during FY26.

This supports recurring prescription demand.

Zydus has another earnings engine that Lupin does not

Consumer Wellness generated approximately ₹1,429 crore of Q1 revenue at the consolidated Zydus level.

Reported segment growth exceeded 60% because of the enlarged business following acquisition activity.

Brands span food, nutrition, skincare and wellness products.

This creates business-model diversification outside prescription pharmaceuticals.

Consumer diversification can reduce pharma volatility

Consumer brands are not exposed to US generic price erosion or FDA ANDA competition.

They have different risks:

• advertising cost;
• commodity inflation;
• brand competition;
• retail distribution;
• consumer demand.

This makes Zydus a broader life-sciences platform than Lupin.

But Consumer Wellness also contributed to margin dilution

Consumer businesses generally do not carry the same EBITDA profile as limited-competition pharmaceutical products.

Acquisition financing and amortisation can also reduce consolidated profitability.

Zydus's 22% revenue growth therefore should not be interpreted as 22% pharmaceutical profit growth.

International Markets are growing strongly for Zydus

International Markets formulations generated approximately ₹974 crore.

Revenue increased around 34%.

The business benefited from demand across multiple geographies.

Lupin's Emerging Markets revenue grew faster at 51.7%, while its Other Developed Markets increased 48.3%.

Lupin therefore had the stronger overall ex-US international percentage growth in Q1.

Both companies are investing aggressively in R&D

Zydus invested approximately ₹642 crore, equal to 8% of revenue.

Lupin invested approximately ₹608 crore, equal to 7.4% of sales.

Zydus spent slightly more despite having slightly lower revenue.

This reflects its innovation, specialty, biosimilar and generic pipeline.

R&D quality matters more than R&D quantity

High spending creates no shareholder value if products fail.

The relevant measures are:

• approvals;
• commercial launches;
• market share;
• gross margin;
• incremental ROCE.

Saroglitazar therefore provides a particularly visible test of Zydus's innovation spending.

Zydus is also investing heavily in capacity

Organic Q1 capex was approximately ₹585 crore.

The company continues investing across formulations, biologics, specialty products and other operations.

That capital needs to generate future growth without pushing ROCE lower.

Lupin's Q1 capex was much lower

Lupin invested approximately ₹279 crore in Q1 capex.

This partly reflects different investment cycles.

Lupin is currently harvesting earnings from years of prior complex-product investment.

Zydus is investing through a branded and innovation expansion phase.

Balance-sheet quality currently favours Lupin

Zydus's leverage remains manageable.

But Lupin's net-cash position gives it greater immediate financial flexibility.

Zydus's debt has partly funded strategic expansion

The company is deliberately building:

• specialty products;
• US branded capabilities;
• consumer platforms;
• innovation;
• MedTech;
• international franchises.

This can create a stronger company if returns exceed the cost of capital.

It can dilute shareholder value if acquired assets fail to earn adequate returns.

ROCE currently favours Lupin by a wide margin

Lupin leads both ROCE and ROE.

The free-cash-flow gap is smaller.

Both companies have generated substantial cash over five years.

Lupin's current earnings acceleration has simply pushed its return ratios much higher.

Valuation also currently favours Lupin

The market capitalisations are almost identical.

Zydus is valued around ₹1.15 lakh crore.

Lupin is valued around ₹1.14 lakh crore.

That makes the comparison unusually clean.

For nearly the same market value, Lupin currently provides more earnings

Lupin generated:

• slightly more revenue;
• around 34% more EBITDA;
• around 51% more PAT;
• higher ROCE;
• net cash.

This explains the lower P/E.

On current earnings alone, Lupin is clearly cheaper.

Why might investors still choose Zydus?

Because current earnings are not the only thing that matters.

Zydus offers:

• Saroglitazar innovation upside;
• a growing US branded franchise;
• 20% India growth;
• consumer diversification;
• biosimilar optionality;
• innovation-led R&D.

If those investments succeed, future earnings can look very different from Q1.

The price-to-book comparison captures this trade-off

Zydus trades at a lower price-to-book ratio than Lupin.

Lupin earns much higher current ROE.

Investors therefore pay more per rupee of Lupin book value because those assets currently produce more earnings.

Zydus needs innovation and branded growth to close that return gap.

One-year share-price performance is almost identical

Bull Run's latest one-year return is approximately 15.9% for Zydus.

Lupin is up approximately 14.0%.

Unlike several other pharma comparisons, recent share momentum therefore does not explain the valuation difference.

The gap comes primarily from earnings and return ratios.

What must Zydus prove?

• Saroglitazar needs successful FDA review and commercial preparation.
• US branded revenue should keep increasing as a share of North America.
• India needs sustained double-digit growth.
• Q1 margin compression should not become structural.
• Consumer Wellness acquisitions need attractive returns.
• Net leverage should remain controlled.
• R&D needs visible commercial conversion.

What must Lupin prove?

• US growth must survive exclusivity normalization.
• Complex products need continuous replenishment.
• 31%-plus Q1 EBITDA margin should prove reasonably durable.
• India formulations need continued double-digit growth.
• Biosimilars should scale profitably.
• Net cash should be allocated productively.
• ROCE should remain high through the next product cycle.

What could make Zydus outperform Lupin?

A successful specialty transformation.

If Saroglitazar is approved and builds a meaningful US franchise while Rolvedon, orphan products and 505(b)(2) assets expand, Zydus's US economics can become less generic-dependent.

That can support higher and more durable valuation multiples.

What could make Lupin outperform Zydus?

Simply maintaining current differentiated-product execution.

Lupin does not need a blockbuster proprietary-drug approval to justify a 20.6x P/E.

If complex US products continue replacing normalizing launches and India remains strong, the current earnings multiple offers a much lower hurdle.

Which has the stronger current US business?

Lupin.

It generated approximately US$366 million and grew 42.9% versus Zydus at approximately US$327 million, down slightly year on year.

Which has the stronger India growth?

Zydus on percentage growth.

India formulations grew 20% versus Lupin India sales growth of 13.9%.

Lupin remained larger in absolute revenue.

Which has the stronger current margins?

Lupin.

EBITDA margin was 31.4% versus Zydus at 24.1%.

Which has the more interesting innovation catalyst?

Zydus Lifesciences.

Saroglitazar's November 27, 2026 FDA target action date creates a defined near-term regulatory catalyst for an internally developed drug.

Which has the stronger balance sheet?

Lupin.

It reported a net-cash position while Zydus carried moderate net debt.

Which stock has the stronger valuation?

Lupin.

It trades around 20.6x trailing earnings versus Zydus around 25.6x while currently producing higher ROCE and PAT.

Which is better: Zydus Lifesciences or Lupin?

Lupin currently has the stronger valuation-adjusted operating profile. The two companies have almost the same revenue and market capitalisation, but Lupin generates materially more EBITDA and PAT, earns higher ROCE, carries net cash and trades at a lower P/E.

Zydus currently has the more interesting innovation-led upside. India formulations are growing 20%, branded products are becoming more important in the US, and Saroglitazar could create a proprietary US specialty franchise if approved.

The comparison therefore comes down to certainty versus optionality.

Lupin's current earnings are much stronger.

Zydus's future earnings have more visible proprietary-drug optionality.

At September 2026 valuations, Lupin is the stronger current combination of growth, profitability, ROCE and value. Zydus becomes more compelling if its US branded transformation succeeds—particularly if Saroglitazar converts from regulatory catalyst into a commercially meaningful specialty product.

Frequently asked questions